Eli Lilly is joining many of its drug industry peers in quest of an efficient coronavirus therapy.
The $120 billion pharmaceutical wide finalized a collaboration with AbCellera, a non-public Canadian lifestyles sciences company, on Thursday.
The aim is to s…
© 2020 People & Tech Ltd. Trademarks and brands are the property of their respective owners.